Aralez Pharmaceuticals Inc (ARLZ.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|63||2016||Independent Chairman of the Board|
|58||2016||President, Chief Business Officer|
|64||2016||Chief Executive Officer, Director|
|42||2017||Head of Finance and Interim Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer|
|45||2016||Executive Vice President - Human Resources and Administration|
- BRIEF-Aralez Pharmaceuticals Announces Discontinuation Of U.S. Commercial Operations, With Reductions In Operating Expenses
- BRIEF-Aralez Pharmaceuticals Reports Q1 Loss Per Share Of $0.29
- BRIEF-Aralez Pharmaceuticals Says Unit Entered Into Modification Of Contract
- BRIEF-Aralez Pharmaceuticals Inc - On March 13, Board Appointed Michael Kaseta As Company's CFO - SEC Filing
- BRIEF-Aralez Pharmaceuticals Posts Q4 Loss Per Share $0.68